{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"LXMICYYYVWWGAM-LFIBNONCSA-N","prefName":"Cannabigerobutol","symbol":"CBGB","iupacName":"5-butyl-2-[(2E)-3,7-dimethylocta-2,6-dienyl]benzene-1,3-diol","aliases":["CBGB","Cannabigérobutol","Cannabigerobutol","CBG-C4","CBG butylique"],"cas":null,"pubchemCid":"131973883","chebiId":null,"smiles":"CCCCC1=CC(=C(C(=C1)O)C/C=C(\\C)/CCC=C(C)C)O","molecularFormula":"C20H30O2","molecularWeight":302.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/131973883"}},"classification":{"family":"mineur","familyLabel":"Minor phytocannabinoid","origin":"natural","originLabel":"Naturel","structuralClassFr":null},"originSynthesis":{"heading":"Biosynthetic pathway","summaryFr":"Biosynthetic pathway: CBGB belongs to the butyl series of cannabinoids, in which the olivetolic acid type precursor carries a four-carbon chain. Its geranylation leads to cannabigerobutolic acid, whose decarboxylation releases CBGB. Because cannabigerol and its homologues are the precursors of the other cannabinoids, they are rapidly converted in the plant and persist there only in small amounts.","originNote":"Cannabis sativa L. (hemp): identified as one of the two main impurities of cannabigerol extracted from hemp, alongside cannabigerovarin.","discovered":""},"pharmacology":{"summaryFr":"Cannabigerobutol (CBGB) is the butyl side-chain homologue of cannabigerol. It was identified in 2021 by Cannazza and Citti's team as one of the two main impurities of commercial cannabigerol extracted from hemp, together with cannabigerovarin, by high-resolution mass spectrometry and then comparison with the synthetic standard; the same study provides its full spectroscopic characterisation and an assay validated between 0.01 and 1.00 µg/mL. A 2022 study prepared a series of CBG homologues by synthesis: in mice, all of them attenuated chemotherapy-induced neuropathic pain to a similar extent at 10 mg/kg, and the short chains, CBGV and CBGB, reduced the viability of colorectal cancer cells more strongly. No CB1 or CB2 affinity and no human data have been published.","receptorSummaryFr":"No affinity constant at CB1 or CB2 has been published for CBGB. The only biological data come from a 2022 study of synthetic CBG homologues: in mice, all the homologues tested reduced chemotherapy-induced neuropathic pain to a similar extent at a dose of 10 mg/kg, and the short-chain homologues, CBGV and CBGB, reduced the viability of cultured colorectal cancer cells more strongly.","binding":[{"target":"CB1","efficacy":"modulator","relativeActivity":5,"reported":"aucune constante d'affinité publiée","confidence":"medium"},{"target":"CB2","efficacy":"modulator","relativeActivity":5,"reported":"aucune constante d'affinité publiée","confidence":"medium"}],"references":[{"label":"Tolomeo et coll., analyse HPLC-UV-HRMS du cannabigérovarine et du cannabigérobutol, les deux impuretés du cannabigérol extrait du chanvre, Journal of Pharmaceutical and Biomedical Analysis 2021","pmid":"34153935","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/34153935/"},{"label":"Raup-Konsavage et coll., synthèse efficace pour modifier la longueur de chaîne latérale des cannabinoïdes et effets sur la chimiothérapie et la douleur neuropathique induite, Biomolecules 2022","pmid":"36551296","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/36551296/"},{"label":"Légifrance, annexe IV de l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://www.legifrance.gouv.fr/loda/article_lc/LEGIARTI000020689963/"},{"label":"PubChem CID 131973883 : cannabigérobutol (identifiants)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/131973883"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":6},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":4},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":4},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":4},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":2}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"unscheduled","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"Not listed in the schedules of the 1961 and 1971 conventions, and with no control measure of its own at European Union level. Concentrated preparations intended for food fall under Regulation (EU) 2015/2283 on novel foods.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Unscheduled substance. CBGB is named in no annex of the order of 22 February 1990 and falls under no generic clause. A homologue of cannabigerol, it lacks the benzo[c]chromene nucleus targeted by the ANSM decision of 22 May 2024. Its presence as an impurity of cannabigerol falls under the framework applicable to hemp.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Tolomeo et coll., analyse HPLC-UV-HRMS du cannabigérovarine et du cannabigérobutol, les deux impuretés du cannabigérol extrait du chanvre, Journal of Pharmaceutical and Biomedical Analysis 2021","pmid":"34153935","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/34153935/"},{"label":"Raup-Konsavage et coll., synthèse efficace pour modifier la longueur de chaîne latérale des cannabinoïdes et effets sur la chimiothérapie et la douleur neuropathique induite, Biomolecules 2022","pmid":"36551296","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/36551296/"},{"label":"Légifrance, annexe IV de l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://www.legifrance.gouv.fr/loda/article_lc/LEGIARTI000020689963/"},{"label":"PubChem CID 131973883 : cannabigérobutol (identifiants)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/131973883"}],"meta":{"slug":"cbgb","url":"https://en.phytogrammes.com/wiki/cbgb","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-11","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}